Sodium butyrate and its synthetic amide derivative modulate nociceptive behaviors in mice

Russo, Roberto; De, Carmen; Avagliano, Carmen; Cristiano, Claudia; Rana, Giovanna La; Raso, Giuseppina Mattace; Canani, Roberto Berni; Meli, Rosaria; Calignano, Antonio

doi:10.1016/j.phrs.2015.11.026

Cited by 57 publications

(44 citation statements)

References 46 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the beneficial effects of oral and topical administration of sodium butyrate on different models of DSS‐induced colitis in mice have already been demonstrated (Vieira et al ., ; Mishiro et al ., ). Recently, we investigated the role of butyrate and FBA in pain behaviour, identifying different and converging non‐genomic and genomic mechanisms of action, which cooperate in nociception maintenance (Russo et al ., ). Notably, we found both compounds had a marked effect on inflammatory visceral pain probably due to a physiological effect of butyrate in the gut and to an elevation in the number of its transporters (i.e.…”

Section: Discussionmentioning

confidence: 97%

An orally administered butyrate‐releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium‐induced murine colitis

Simeoli

Raso

Pirozzi

et al. 2016

British J Pharmacology

Self Cite

100

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

An orally administered butyrate‐releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium‐induced murine colitis

Simeoli

Raso

Pirozzi

et al. 2016

British J Pharmacology

Self Cite

100

View full text Add to dashboard Cite

show abstract

“…Butyrate is a major gut microbiota metabolite able to exert a wide range of beneficial actions at intestinal and extra‐intestinal level . Butyrate modulates intestinal transit time, visceral and central pain perception and gut‐brain axis, and exerts a potent anti‐inflammatory action . The faecal calprotectin features have been explored by only few authors with conflicting results .…”

Section: Discussionmentioning

confidence: 99%

“…34 Butyrate modulates intestinal transit time, visceral and central pain perception and gut-brain axis, and exerts a potent anti-inflammatory action. [35][36][37][38][39][40][41][42][43][44][45][46] The faecal calprotectin features have been explored by only few authors with conflicting results. 47,48 We found a different modulation of calprotectin in responder infants to BB-12…”

Section: Gastroenterology Hepatology and Nutrition (Espghan) Workingmentioning

confidence: 99%

The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB‐12^® in infant colic: A randomised, double blind, placebo‐controlled trial

Nocerino

Filippis

Cecere

et al. 2019

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

Summary Background The pathogenesis of infant colic is poorly defined. Gut microbiota seems to be involved, supporting the potential therapeutic role of probiotics. Aims To assess the rate of infants with a reduction of ≥50% of mean daily crying duration after 28 days of intervention with the probiotic Bifidobacterium animalis subsp. lactis BB‐12® (BB‐12). Secondary outcomes were daily number of crying episodes, sleeping time, number of bowel movements and stool consistency. Methods Randomized controlled trial (RCT) on otherwise healthy exclusively breastfed infants with infant colic randomly allocated to receive BB‐12 (1 × 109 CFU/day) or placebo for 28 days. Gut microbiota structure and butyrate, beta‐defensin‐2 (HBD‐2), cathelicidin (LL‐37), secretory IgA (sIgA) and faecal calprotectin levels were assessed. Results Eighty infants were randomised, 40/group. The rate of infants with reduction of ≥50% of mean daily crying duration was higher in infants treated with BB‐12, starting from the end of 2nd week. No infant relapsed when treatment was stopped. The mean number of crying episodes decreased in both groups, but with a higher effect in BB‐12 group (−4.7 ± 3.4 vs −2.3 ± 2.2, P < 0.05). Mean daily stool frequency decreased in both groups but the effect was significantly higher in the BB‐12 group; stool consistency was similar between the two groups. An increase in Bifidobacterium abundance (with significant correlation with crying time reduction), butyrate and HBD‐2, LL‐37, sIgA levels associated with a decrease in faecal calprotectin level were observed in the BB‐12 group. Conclusions Supplementation with BB‐12 is effective in managing infant colic. The effect could derive from immune and non‐immune mechanisms associated with a modulation of gut microbiota structure and function.

show abstract

“…Another group of mice was treated with oral gavage with FBA (30 mg/kg/day), provided by Prof. Calignano (US patent US 2011 00983.19A1; 28 April 2011), daily for 21 days (FBA group). A third group of mice, after 14 days of FBA, received co‐administration of FBA (1 h before i.p.…”

Section: Methodsmentioning

confidence: 99%

The novel butyrate derivative phenylalanine‐butyramide protects from doxorubicin‐induced cardiotoxicity

Russo

Guida

Paparo

et al. 2019

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

AimsButyric acid (BUT), a short chain fatty acid produced daily by the gut microbiota, has proven beneficial in models of cardiovascular diseases. With advancements in cancer survival, an increasing number of patients are at risk of anticancer drug cardiotoxicity. Here we assess whether the novel BUT derivative phenylalanine-butyramide (FBA) protects from doxorubicin (DOXO) cardiotoxicity, by decreasing oxidative stress and improving mitochondrial function.In C57BL6 mice, DOXO produced left ventricular dilatation assessed by echocardiography. FBA prevented left ventricular dilatation, fibrosis and cardiomyocyte apoptosis when co-administered with DOXO. DOXO increased atrial natriuretic peptide, brain natriuretic peptide, connective tissue growth factor, and matrix metalloproteinase-2 mRNAs, which were not elevated on co-treatment with FBA. DOXO, but not FBA + DOXO mice, also showed higher nitrotyrosine levels, and increased inducible nitric oxide synthase expression. Accordingly, DOXO hearts showed lower levels of intracellular catalase vs. sham, while pre-treatment with FBA prevented this decrease. We then assessed for reactive oxygen species (ROS) emission: DOXO induced increased activity of mitochondrial superoxide dismutase and higher production of H 2 O 2 , which were blunted by FBA pre-treatment. FBA also ameliorated mitochondrial state 3 and state 4 respiration rates that were compromised by DOXO. Furthermore, in DOXO animals, the mitochondrial degree of coupling was significantly increased vs. sham, while FBA was able to prevent such increase, contributing to limit ROS production, Finally, FBA reduced DOXO damage in human cellular models, and increased the tumour-killing action of DOXO.

show abstract

Sodium butyrate and its synthetic amide derivative modulate nociceptive behaviors in mice

Cited by 57 publications

References 46 publications

An orally administered butyrate‐releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium‐induced murine colitis

An orally administered butyrate‐releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium‐induced murine colitis

The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB‐12^® in infant colic: A randomised, double blind, placebo‐controlled trial

The novel butyrate derivative phenylalanine‐butyramide protects from doxorubicin‐induced cardiotoxicity

Contact Info

Product

Resources

About

Sodium butyrate and its synthetic amide derivative modulate nociceptive behaviors in mice

Cited by 57 publications

References 46 publications

An orally administered butyrate‐releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium‐induced murine colitis

An orally administered butyrate‐releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium‐induced murine colitis

The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB‐12® in infant colic: A randomised, double blind, placebo‐controlled trial

The novel butyrate derivative phenylalanine‐butyramide protects from doxorubicin‐induced cardiotoxicity

Contact Info

Product

Resources

About

The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB‐12^® in infant colic: A randomised, double blind, placebo‐controlled trial